title: Metabolic syndrome in prostate cancer: impact on risk and outcomes.
abstract: Androgen-deprivation therapy (ADT) is a fundamental element of treatment for nonlocalized prostate cancer and for patients with high-risk disease who are not candidates for radical treatment. ADT has been linked to metabolic syndrome, which involves changes in metabolic factors. While distinct from classic metabolic syndrome, this type does include changes in body composition, lipid profiles and insulin resistance. The constellation of risk factors may be associated with cardiovascular morbidity and the onset of diabetes mellitus. Physicians should discuss in detail the risk and benefits of ADT, as well as any needed lifestyle modifications with patients before beginning therapy.
authors.affiliation: Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Fatima H
authors.initials: FH
authors.lastname: Karzai
authors.affiliation: Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.affiliation: Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists
keywords: androgen receptor; androgen-deprivation therapy; cardiovascular risk; diabetes; gonadotropin-releasing hormone agonist/antagonist; hypertriglyceridemia; insulin resistance; metabolic syndrome; prostate cancer